Credit: Sugandh Khandelwal
Dr. Agarwal’s Healthcare IPO opens for subscription on January 29, 2025, showcasing its leadership in eye care services with a strong presence. According to the CRISIL MI&A Report for Financial Year 2024, the firm held approximately 25% of the total eye care service market share in India.The company aims to utilize the proceeds for debt repayment and strategic acquisitions. The IPO price band is set at ₹382 to ₹402 per share.
With a strong operational history, the company is committed to meeting all the needs of its patients throughout their eye treatment journey. As of September 30, 2024, the company’s network consisted of 209 facilities. The CRISIL MI&A Report also highlighted that the firm had the highest number of eye care service facilities in India compared to its listed and unlisted peers at that time.The allotment finalization date is expected on Monday, February 3, 2025, and the shares are tentatively scheduled to be listed on BSE and NSE on Wednesday, February 5, 2025.Based in Tamil Nadu, the company operates 165 facilities across India and 15 international centers, including 9 in Africa.
It provides a comprehensive range of eye care services, including cataract and refractive surgeries, and also offers optical products, contact lenses, accessories, and pharmaceuticals related to eye care. Retail investors will need to invest a minimum of ₹14,070. For small non-institutional investors (sNII), the minimum lot size is 15 lots (525 shares), requiring an investment of ₹2,11,050. For large non-institutional investors (bNII), the minimum lot size is 72 lots (2,520 shares), amounting to ₹10,13,040.
The book-running lead managers for the issue are Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Pvt Ltd, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited. KFin Technologies Limited is the registrar for the IPO.
